September 25, 2024
Vilobelimab demonstrates significant improvement in reduction of draining tunnels
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today said that Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR